Designing steriod receptor-based radiotracers to image breast and prostate tumors
- Univ. of Illinois, Urbana, IL (United States)
Imaging of breast or prostate cancers based on their content of steroid receptors poses a major challenge in the design of radiotracers. Receptors for steroid hormones are proteins that interact at specific sites in chromatin. Several analogs of estrogens, progestins and androgens have been radiolabeled and evaluated both in vitro and in vivo for receptor binding affinity and selectivity. Breast tumors in patients have been imaged with [{sup 18}F]fluoroestradiol. Scintigraphic images with radiolabeled progestin analogs may be useful for monitoring the efficacy of tamoxifen treatment in breast cancer patients. Tissue distribution and imaging studies in animals with fluorine-substituted androgens indicate that it may be possible to develop a steroid receptor-based radiotracer for staging prostate cancer. Radiochemists are reporting some progress in labeling steroid receptor ligands with {sup 99m}Tc. By using the techniques of molecular nuclear medicine, new imaging procedures could be developed that might provide more precise information to help characterize disease and effect treatment decisions in patients with breast or prostate cancers. 55 refs., 4 figs., 4 tabs.
- OSTI ID:
- 250035
- Journal Information:
- Journal of Nuclear Medicine, Vol. 36, Issue 6; Other Information: PBD: Jun 1995
- Country of Publication:
- United States
- Language:
- English
Similar Records
Radiolabeled androgens and progestins as imaging agents for tumors of the prostate and breast
Radiolabeled androgens and progestins as imaging agents for tumors of the prostate and breast. Technical progress report, February 1, 1992--January 31, 1993